BioCryst Pharmaceuticals | BCRX - Заемный капитал





Заемный капитал Изменить Дата
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
BioCryst Pharmaceuticals USD 395.4M 203K 2026-06
Chugai Pharma JPY 4.53B 1.95B 2024-12
Daiichi Sankyo JPY 500B 199.92B 2026-06
DBV Technologies USD 0 0 2025-03
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 13.95B 65M 2026-06
Glaxosmithkline GBP 18.53B 1.29B 2026-03
Incyte USD 28.42M 994K 2026-06
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
Karyopharm Therapeutics USD 264.49M 13.73M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novavax USD 246.3M 200K 2025-12
PTC Therapeutics USD 535.52M 248.58M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12